Is a delay in the introduction of human papillomavirus-based cervical screening affordable?
Open Access
- 3 October 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 26 (1) , 44-49
Abstract
Objective: It often takes considerable time for sufficient evidence to accumulate to support implementation of new methods in routine screening. Where national screening programmes are already effective, switching to a more sensitive screening test may not be a priority. Although risk associated with overly rapid implementation exists, postponement is also associated with a (to date unquantified) missed opportunity to prevent deaths. This risk tends not to be addressed where effective screening methods are already in use. We here estimate the monetary value of a one-year delay in replacing cytology cervical screening with human papillomavirus testing. Methods: Using a previously validated model, we calculated the number of incident and fatal cervical cancers that would be diagnosed by 2030 in England, under the assumption that human papillomavirus testing replaces cytology in 2020 rather than 2019, and the monetary value of the quality-adjusted life years lost in preventable cases. Results: A one-year delay in the implementation of human papillomavirus screening would miss the opportunity to prevent 581 cases of cervical cancer, and lead to a loss of 1595 quality-adjusted life years (3.5% discount rate) with a monetary value of £32 million (at £20,000 per quality-adjusted life year). Conclusion: This is a measurable loss and should be considered in prioritising decision-making in screening.Keywords
Funding Information
- Cancer Research UK (C8162/A16872)
This publication has 16 references indexed in Scilit:
- Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trialsThe Lancet, 2014
- Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission modelBMJ, 2014
- Population Norms for the EQ-5D2013
- Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission modelBMJ, 2011
- ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screeningHealth Technology Assessment, 2009
- Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening TestJNCI: Journal of the National Cancer Institute, 2008
- Human Papillomavirus and Papanicolaou Tests to Screen for Cervical CancerNew England Journal of Medicine, 2007
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.Proceedings of the National Academy of Sciences of the United States of America, 1983